Why SIBO Keeps Coming Back: Understanding Recurrence and the Underlying Causes

One of the most frustrating features of small intestinal bacterial overgrowth (SIBO) is its tendency to return. Someone may complete a course of antibiotics or antimicrobial herbs, experience substantial improvement in bloating, abdominal discomfort and bowel function, only to find the same symptoms gradually returning weeks or months later.

This does not necessarily mean that treatment was unsuccessful. Recurrent SIBO often reflects a more fundamental problem: the microbial overgrowth may be a consequence of impaired gastrointestinal function rather than the primary problem itself.

This distinction is important. If microbial numbers are repeatedly reduced without changing the intestinal environment that allowed them to accumulate, recurrence is not especially surprising. The more useful question therefore becomes not simply how to treat SIBO again, but why the small intestine is allowing it to re-establish.

How Common Is SIBO Recurrence?

There is surprisingly little high-quality research examining long-term recurrence. One frequently cited prospective study followed 80 people whose glucose breath tests had normalised following rifaximin treatment. SIBO had returned in 12.6% after three months, 27.5% after six months and 43.7% after nine months (Lauritano et al. 2008).

This was a relatively small and older study, so these figures should not be assumed to apply to everyone with SIBO. Nevertheless, they demonstrate an important point: recurrence following apparently successful treatment is common.

For recurrent cases, treatment therefore needs to look beyond microbial eradication alone.

SIBO Is Often a Problem of Impaired Clearance

The small intestine is not sterile, but microbial populations are normally considerably lower than in the colon. Several mechanisms help maintain this balance, including gastric acid, bile and pancreatic secretions, intestinal immune function and gastrointestinal motility.

One of the most important is the migrating motor complex (MMC). The MMC produces cyclical waves of muscular activity through the stomach and small intestine, particularly between meals, helping move residual food, secretions and microorganisms towards the colon. It can effectively be thought of as part of the small intestine's housekeeping system.

When this clearance mechanism becomes impaired, intestinal contents remain in the small bowel for longer, creating greater opportunity for microbial proliferation and fermentation. Dysmotility is therefore an important recognised factor in the development of SIBO (Knez et al. 2024).

This helps explain why antimicrobial treatment can produce marked improvement without necessarily preventing recurrence. The microbial population may have been reduced, but if small intestinal clearance remains slow, the conditions favouring overgrowth remain.

Constipation, Methane and the Recurrence Cycle

Constipation is particularly relevant when SIBO repeatedly returns.

What has traditionally been called ‘methane SIBO’ is now more accurately termed intestinal methanogen overgrowth (IMO). Methane is produced by archaea rather than bacteria, and methanogens can inhabit both the small and large intestine.

Methane production is consistently associated with constipation and slower gastrointestinal transit. This can create a self-reinforcing pattern in which slow transit favours methanogen persistence, while methane production may itself further impair motility. Current breath-testing guidance therefore distinguishes IMO from hydrogen-predominant SIBO and recommends measuring methane alongside hydrogen (Perets et al. 2026).

For someone with recurrent methane-positive testing, antimicrobial treatment without adequately improving constipation and motility may therefore have limited long-term benefit. In these cases, restoring bowel regularity is not simply supportive care; it is part of addressing the physiology that may be allowing the overgrowth to persist.

Other Factors That Can Predispose to Recurrence

Normal gastrointestinal anatomy also protects against overgrowth. Diverticula, strictures, blind loops and anatomical changes following gastrointestinal or bariatric surgery can create areas of stagnation where microorganisms accumulate.

Digestive physiology and medication use may also be relevant. Gastric acid provides an important antimicrobial barrier, and a 2025 meta-analysis found that proton-pump inhibitor (PPI) use was associated with approximately twice the odds of SIBO, although there was considerable variation between studies (Khurmatullina et al. 2025). Medications that slow gastrointestinal transit, particularly opioids, may also increase susceptibility.

A number of underlying conditions can contribute through altered motility or digestive function, including diabetes with autonomic neuropathy, gastroparesis, hypothyroidism, systemic sclerosis, coeliac disease, inflammatory bowel disease and chronic pancreatitis (Efremova et al. 2023). Previous gastrointestinal infection is another consideration, particularly when bowel function never fully returned to normal afterwards.

These factors become increasingly important when someone responds well to treatment but repeatedly relapses.

Antimicrobials and Diet: Useful, but Not the Whole Answer

Rifaximin is one of the best-studied pharmaceutical treatments for SIBO. A systematic review and meta-analysis reported an overall eradication rate of approximately 71%, although the included studies were heterogeneous and generally of limited quality (Gatta and Scarpignato 2017).

Botanical antimicrobial medicines are also commonly used within naturopathic practice and can be useful in selected patients. However, the clinical evidence remains less developed. A 2024 randomised trial found that adding herbal supplements, probiotics and prebiotics to antibiotics and dietary treatment did not significantly improve breath-gas normalisation, although additional symptom improvement was seen in some participants, particularly those with methane-positive testing (Redondo-Cuevas et al. 2024).

I therefore see antimicrobial herbs as one component of treatment rather than the complete strategy. If symptoms reliably improve during treatment and return soon afterwards, continually escalating antimicrobial combinations may overlook the reason the overgrowth is returning.

Diet follows a similar principle. Temporarily reducing highly fermentable carbohydrates can substantially improve bloating, gas and abdominal discomfort because less substrate is available for microbial fermentation. However, symptom improvement does not necessarily mean the underlying SIBO has resolved, and evidence remains insufficient to recommend any particular diet as an established method of eradicating SIBO (Souza et al. 2022).

Long-term restriction can also become counterproductive when progressively more foods are removed with every relapse. I generally use dietary restriction strategically, with the longer-term aim of increasing dietary diversity and tolerance as gastrointestinal function improves.

Meal timing may also be relevant because the MMC predominantly operates between meals. Allowing appropriate intervals between eating therefore has a reasonable physiological rationale, although direct evidence that meal spacing itself prevents SIBO recurrence remains limited.

Mould-Related Illness and SIBO

I see a large number of patients with mould-related illness who also have SIBO or significant gastrointestinal dysfunction. Two patterns have become particularly apparent in my clinical practice. Some people have pre-existing gut problems that become substantially worse following mould exposure, while another group develop new gastrointestinal symptoms despite having little or no previous history. In recent years, constipation-predominant SIBO or IMO has been the pattern I have encountered most frequently in this latter group. This is a clinical observation rather than an association that has yet been clearly demonstrated in human research.

There is emerging biological plausibility for an interaction, although this should not be confused with evidence that mould directly causes SIBO. A recent review found that mycotoxins can alter microbial composition and short-chain fatty acid production and affect epithelial tight-junction integrity, while intestinal microorganisms can themselves influence mycotoxin metabolism and biotransformation (Mafe and Büsselberg 2026). Much of this research remains experimental and focuses on dietary mycotoxin exposure rather than water-damaged buildings. I therefore consider mould-related illness as one possible contributor to altered gastrointestinal function within the broader clinical picture rather than assuming a simple mould-to-SIBO causal pathway.

SIBO and Chronic Kidney Disease

Chronic kidney disease (CKD) is another setting in which altered intestinal motility may contribute to SIBO. Constipation, uraemia, dietary restriction, medication use and slower gastrointestinal transit can all affect the intestinal environment as kidney function declines.

Importantly, the evidence is not limited to generalised gut dysbiosis. A systematic review by Chung et al. (2019) identified research directly examining SIBO in chronic renal failure. In one study of 22 people, direct small intestinal sampling identified SIBO in 36% of participants. Half also demonstrated neuropathic-like small intestinal motility abnormalities, with SIBO present in 55% of those with abnormal motility compared with 18% of those without it, although the study was small and this difference did not reach statistical significance (Strid et al. 2003).

The evidence is older and limited, but the findings are interesting because they again point towards the same underlying mechanism: microbial overgrowth may occur downstream of impaired intestinal motility. This is particularly relevant in CKD, where constipation is common. Treatment also needs to account for kidney function, medication interactions and the safety of herbs, supplements and laxatives that might otherwise be routinely used for SIBO.

Sometimes ‘Recurrent SIBO’ May Not Be SIBO

There is another reason not to automatically reach for another antimicrobial protocol whenever symptoms return: the diagnosis itself is imperfect.

Bloating, abdominal distension, constipation, diarrhoea and abdominal pain can also occur with IBS, visceral hypersensitivity, carbohydrate intolerance, pelvic floor dysfunction, coeliac disease and pancreatic insufficiency.

Breath testing also has limitations and needs to be interpreted alongside symptoms, bowel transit, preparation and the substrate used. Lactulose and glucose breath tests each have advantages and limitations. Lactulose allows fermentation to be assessed throughout the small intestine but can be influenced by oro-caecal transit time, particularly when transit is unusually rapid. Glucose is absorbed more proximally and may therefore be less likely to detect more distal overgrowth (Quigley et al. 2020). For this reason, I interpret breath-test findings within the broader clinical picture rather than relying on a single gas reading or threshold in isolation.

A return of symptoms therefore does not necessarily mean that the same pattern of SIBO or IMO has returned. In persistent cases, reconsidering the wider gastrointestinal picture is preferable to treating presumed overgrowth indefinitely.

My Approach to Recurrent SIBO

From an evidence-informed naturopathic perspective, I approach recurrent SIBO as a problem of the intestinal environment as well as the microbial overgrowth. Antimicrobial treatment can be useful, but I am also assessing bowel regularity, methane production, intestinal motility, digestive function, dietary patterns and the broader factors that may be interfering with normal gastrointestinal function.

Treatment may involve botanical antimicrobials, dietary modification, fibre or prebiotics, probiotics, digestive support and motility-focused interventions, but these need to be individualised and introduced at the appropriate stage. Someone who is significantly constipated and highly fermentative, for example, may initially tolerate prebiotic fibre poorly, whereas it may become considerably more useful as bowel function improves. Depending on the individual, thyroid and metabolic health, medication use, previous gastrointestinal infection, chronic kidney disease, stress and autonomic nervous-system function, and significant environmental exposures may also need to be considered.

The longer-term aim is not to leave someone indefinitely restricting foods or repeatedly taking antimicrobial herbs. It is to restore regular bowel function, improve motility and digestive function, and progressively rebuild dietary tolerance and microbial resilience. For me, successful treatment is therefore not simply a negative breath test. A more meaningful outcome is someone who can eat a broader diet, has substantially improved bowel and digestive function, and remains well without continually returning to antimicrobial treatment.

The Takeaway

SIBO often returns because reducing excessive microorganisms does not necessarily correct the environment that allowed them to accumulate.

For some people, impaired small intestinal motility or constipation appears central. For others, methane production, digestive dysfunction, medications, anatomical changes or another underlying condition may be contributing. In selected patients, mould-related illness or chronic kidney disease may form part of this more complex picture.

This is why recurrent SIBO requires more than repeatedly trying to eradicate bacteria. The more useful clinical question is why the overgrowth developed in the first place, and what needs to change to make the small intestine less favourable to its return.

References

Chung SY, Barnes JL and Astroth KS (2019) ‘Gastrointestinal microbiota in patients with chronic kidney disease: a systematic review’, Advances in Nutrition, 10(5):888–901, doi:10.1093/advances/nmz028.

Efremova I, Maslennikov R, Poluektova E, Vasilieva E, Zharikov Y, Suslov A, Letyagina Y, Kozlov E, Levshina A and Ivashkin V (2023) ‘Epidemiology of small intestinal bacterial overgrowth’, World Journal of Gastroenterology, 29(22):3400–3421, doi:10.3748/wjg.v29.i22.3400.

Gatta L and Scarpignato C (2017) ‘Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth’, Alimentary Pharmacology & Therapeutics, 45(5):604–616, doi:10.1111/apt.13928.

Khurmatullina AR, Andreev DN, Kucheryavyy YA, Sokolov FS, Beliy PA, Zaborovskiy AV and Maev IV (2025) ‘The duration of proton pump inhibitor therapy and the risk of small intestinal bacterial overgrowth: a systematic review and meta-analysis’, Journal of Clinical Medicine, 14(13):4702, doi:10.3390/jcm14134702.

Knez E, Kadac-Czapska K and Grembecka M (2024) ‘The importance of food quality, gut motility, and microbiome in SIBO development and treatment’, Nutrition, 124:112464, doi:10.1016/j.nut.2024.112464.

Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Novi M, Sottili S, Vitale G, Cesario V, Serricchio M, Cammarota G, Gasbarrini G and Gasbarrini A (2008) ‘Small intestinal bacterial overgrowth recurrence after antibiotic therapy’, American Journal of Gastroenterology, 103(8):2031–2035, doi:10.1111/j.1572-0241.2008.02030.x.

Mafe AN and Büsselberg D (2026) ‘Microbiome–mycotoxin interactions and probiotic strategies: implications for gut health and cancer’, Frontiers in Nutrition, 13:1783295, doi:10.3389/fnut.2026.1783295.

Perets TT, Thurm T, Ben-Yehoyada M, Deutsch L, Ron Y, Baruch R, Niv E, Hershcovici T, Picard O, Engel T, Zangen T, Frishman S and Dickman R (2026) ‘A national consensus guideline on the performance and interpretation of hydrogen- and methane-based breath tests for carbohydrate malabsorption, small intestinal bacterial overgrowth, and intestinal methanogen overgrowth’, Annals of Gastroenterology, 39(4):383–389, doi:10.20524/aog.2026.1082.

Quigley EMM, Murray JA and Pimentel M (2020) ‘AGA clinical practice update on small intestinal bacterial overgrowth: expert review’, Gastroenterology, 159(4):1526–1532, doi:10.1053/j.gastro.2020.06.090.

Redondo-Cuevas L, Belloch L, Martín-Carbonell V, Nicolás A, Alexandra I, Sanchis L, Ynfante M, Colmenares M, Mora M, Reyes Liebana AR, Antequera B, Grau F, Molés JR, Cuesta R, Díaz S, Sancho N, Tomás H, Gonzalvo J, Jaén M, Sánchez E, Garayoa A, Moreno N, Gallén A, Cortés-Castell E and Cortés-Rizo X (2024) ‘Do herbal supplements and probiotics complement antibiotics and diet in the management of SIBO? A randomized clinical trial’, Nutrients, 16(7):1083, doi:10.3390/nu16071083.

Souza C, Rocha R and Cotrim HP (2022) ‘Diet and intestinal bacterial overgrowth: is there evidence?’, World Journal of Clinical Cases, 10(15):4713–4716, doi:10.12998/wjcc.v10.i15.4713.

Strid H, Simrén M, Stotzer P-O, Ringström G, Abrahamsson H and Björnsson ES (2003) ‘Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth’, Digestion, 67(3):129–137, doi:10.1159/000071292.